UTHR

Q: What is the price of United Therapeutics (UTHR) today?

The price of United Therapeutics (UTHR) today is US$ 440,00, with a variation of 24.18% compared to the last year. The price of United Therapeutics (UTHR) started the year trading around US$ 352,84 and today it is at US$ 440,00. Follow the real-time price chart, the historical price of United Therapeutics (UTHR), and stock data from Ibovespa and international markets.

Q: When does United Therapeutics (UTHR) pay dividends?

United Therapeutics (UTHR) did not distribute dividends in the last year.

Q: United Therapeutics (UTHR) is it worth it?

Currently, United Therapeutics (UTHR) is priced at US$ 440,00, with a P/E of 16,41%, representing a deviation of 14,48% from its historical average P/E. In the last year, the stock showed a variation of 24.18% in its price and distributed US$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was 24,18%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How to buy stocks of United Therapeutics (UTHR)?

Investing in stocks of United Therapeutics (UTHR) can be done in two ways: by buying the stock no exterior. A stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much do 100 stocks of United Therapeutics (UTHR) yield today?

The yield of United Therapeutics (UTHR) was 10,97% in the last month, 24,18% in the last year and 322,06% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of US$ 0,00 in dividends, um Dividend Yield de 0,00%.If you wanted to buy 100 stocks of United Therapeutics (UTHR) today, the total investment would be US$ 44.000,00, based on the current price of US$ 440,00.If past performance were to repeat, the return on your investment would be:In 1 year: US$ 54.639,20In 5 years: US$ 185.706,40In 10 years: 157.040,40It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

United Therapeutics Corporation

Price

US$ 440,00

variation (12m)

24,18%

p/l

16,41

p/vp

2,84

DIVIDEND YIELD

0,00%

price UTHR

BVMF

UTHR

If you had invested

years ago

6 months

1 year

5 years

10 years

ago, today you would have

ago, today you would have:

*The figure considers the reinvestment of dividends.

Profitability of UTHR

1 month

3 months

1 year

2 years

5 years

10 years

profitability

1 month

10,97%

3 months

48,89%

1 year

24,18%

2 years

89,49%

5 years

322,06%

10 years

256,91%

real profitability

profitability minus inflation.

1 month

10,97%

3 months

48,34%

1 year

18,73%

2 years

72,95%

5 years

211,89%

10 years

113,69%

Indicators UTHR

check out the fundamentals of United Therapeutics shares

P/E

16,41

Sector: -3,47 Industry: -3,47

P/SALES RATIO (PSR)

6,52

Sector: -4,23 Industry: -4,23

P/BV

2,84

Sector: 1,89 Industry: 1,89

DIVIDEND YIELD (DY)

0,00%

Sector: - Industry: -

ROA

15,71%

Sector: -63,87% Industry: -63,87%

ROE

17,32%

Sector: -70,87% Industry: -70,87%

ROIC

27,27%

Sector: -2.084,36% Industry: -2.084,36%

NET MARGIN

39,73%

Sector: -41,75% Industry: -41,75%

GROSS MARGIN

89,01%

Sector: 38,19% Industry: 38,19%

OPERATING MARGIN

48,57%

Sector: -41,04% Industry: -41,04%

P/EBITDA

11,67

Sector: -3,65 Industry: -3,65

P/EBIT

12,24

Sector: -3,64 Industry: -3,64

P/ASSET

2,58

Sector: 1,41 Industry: 1,41

BVPS

159,41

Sector: 1,84 Industry: 1,84

EPS

27,61

Sector: -2,20 Industry: -2,20

EQUITY / ASSETS

0,91

Sector: 0,42 Industry: 0,42

CAGR REVENUES 5 YEARS

15,73%

Sector: - Industry: -

CAGR PROFITS 5 YEARS

17,78%

Sector: - Industry: -

FAIR PRICE OF United Therapeutics ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Price

The Fair Price formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

US$ 440,00

Fair Price

US$ 0,00

Upside Potencial de rentabilidade.

-28,48%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

UTHR indicators history

DRAG THE FRAME TO SEE MORE DATA

Stocks comparator

DRAG THE FRAME TO SEE MORE DATA

	p/l	p/vp	ROE	dy	market value	net margin
JNJ	17,80	5,78	32,50%	2,69%	US$ 453,87 B	27,75%
PFE	16,92	1,75	10,33%	6,25%	US$ 155,60 B	15,13%
ABBV	108,79	-2.966,40	-2.726,81%	2,79%	US$ 409,36 B	6,45%
NVO	16,20	10,21	62,99%	2,83%	US$ 265,17 B	34,74%
MRK	12,67	4,56	36,03%	3,59%	US$ 223,87 B	28,16%
AZN	28,39	5,90	20,79%	1,83%	US$ 264,46 B	16,23%
BMY	17,97	5,29	29,44%	5,41%	US$ 92,49 B	10,71%
GILD	19,99	7,16	35,82%	2,79%	US$ 140,30 B	24,71%
ZTS	24,61	13,09	53,20%	1,32%	US$ 65,16 B	28,00%
HALO	14,26	25,08	175,93%	0,00%	US$ 8,35 B	48,21%
REGN	13,97	2,10	15,06%	0,44%	US$ 63,00 B	31,83%
AMGN	30,70	21,58	70,29%	3,15%	US$ 160,26 B	14,67%
VRTX	28,59	6,03	21,11%	0,00%	US$ 103,65 B	31,22%
MCK	24,89	-106,90	-429,55%	0,40%	US$ 92,26 B	0,97%
CAH	26,56	-13,96	-52,54%	1,31%	US$ 36,76 B	0,60%
ADMA	17,05	8,87	52,03%	0,00%	US$ 3,53 B	43,51%
BIIB	13,23	1,33	10,08%	0,00%	US$ 23,50 B	17,46%

comparison of UTHR with indexes

If you had invested (change) 2 years years ago, ago, today you would have

R$ 1.000,00 in PETR4 you would have R$ 2.294,60

R$ 1.000,00 in LEVE3 you would have R$ 5.240,60

*The value considers the reinvestment of dividends.

Dividend History UTHR

current DY: 0,00%

5-year average DY: 0,00%

no dividend paid in the period.

ABOUT THE COMPANY United Therapeutics

United Therapeutics Corporation

Average user rating I10

4.0 (2 people)

Estados Unidos

29 years

Foundation: 1996

1999

Year of debut on the stock exchange - 26 years

920

Employees

The Company United Therapeutics Corporation (Estados Unidos), is listed on Nasdaq with a market value of $ 20,39 Billions, having a net worth of $ 7,17 Billions.

With a total of 920 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 3,13 Billions, which generated a profit in the amount of $ 1,24 Billion.

As for its main indicators, the Company has a P/E ratio of 16,41, a P/BV ratio of 2,84 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker UTHR.

Market value

US$ 20,39 Billions

Net worth

US$ 7,17 Billions

US$ 7.173.600.000,00

Assets

US$ 7,91 Billions

US$ 7.908.000.000,00

Total Number of Shares

45,00 Milhões

45.000.000

Average Daily Trading Volume

US$ 879,59 Thousand

US$ 879.588,58

Sector

Health Care

Industry

Biotechnology

UTHR

UTHR revenue and profits

UTHR results

DRAG THE FRAME TO SEE MORE DATA

UTHR cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

US$ - -0,00% (12M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 763,55 51,69% (12M)

P/L

24,89

0,40%

ROE

-429,55%

P/VP

-106,90

CAH - Cardinal Health

US$ 156,88 42,09% (12M)

P/L

26,56

1,31%

ROE

-52,54%

P/VP

-13,96

JNJ - Johnson & Johnson

US$ 190,72 21,94% (12M)

P/L

17,80

2,69%

ROE

32,50%

P/VP

5,78

MRK - Merck & Co.

US$ 85,99 --18,73% (12M)

P/L

12,67

3,59%

ROE

36,03%

P/VP

4,56

ABBV - AbbVie

US$ 230,50 23,82% (12M)

P/L

108,79

2,79%

ROE

-2.726,81%

P/VP

-2.966,40

PFE - Pfizer

US$ 24,78 --8,77% (12M)

P/L

16,92

6,25%

ROE

10,33%

P/VP

1,75

AZN - AstraZeneca

US$ 84,53 11,61% (12M)

P/L

28,39

1,83%

ROE

20,79%

P/VP

5,90

BFRA - Biofrontera

US$ - -0,00% (12 M)

P/L

0,00

0,00%

ROE

-893,55%

P/VP

0,00

MCK - McKesson

US$ 763,55 51,69% (12 M)

P/L

24,89

0,40%

ROE

-429,55%

P/VP

-106,90

CAH - Cardinal Health

US$ 156,88 42,09% (12 M)

P/L

26,56

1,31%

ROE

-52,54%

P/VP

-13,96

JNJ - Johnson & Johnson

US$ 190,72 21,94% (12 M)

P/L

17,80

2,69%

ROE

32,50%

P/VP

5,78

MRK - Merck & Co.

US$ 85,99 --18,73% (12 M)

P/L

12,67

3,59%

ROE

36,03%

P/VP

4,56

ABBV - AbbVie

US$ 230,50 23,82% (12 M)

P/L

108,79

2,79%

ROE

-2.726,81%

P/VP

-2.966,40

PFE - Pfizer

US$ 24,78 --8,77% (12 M)

P/L

16,92

6,25%

ROE

10,33%

P/VP

1,75

AZN - AstraZeneca

US$ 84,53 11,61% (12 M)

P/L

28,39

1,83%

ROE

20,79%

P/VP

5,90

Frequently Asked Questions

What is the price of United Therapeutics (UTHR) today?

The price of United Therapeutics (UTHR) today is US$ 440,00, with a variation of 24.18% compared to the last year. The price of United Therapeutics (UTHR) started the year trading around US$ 352,84 and today it is at US$ 440,00. Follow the real-time price chart, the historical price of United Therapeutics (UTHR), and stock data from Ibovespa and international markets.

When does United Therapeutics (UTHR) pay dividends?

United Therapeutics (UTHR) did not distribute dividends in the last year.

United Therapeutics (UTHR) is it worth it?

Currently, United Therapeutics (UTHR) is priced at US$ 440,00, with a P/E of 16,41%, representing a deviation of 14,48% from its historical average P/E. In the last year, the stock showed a variation of 24.18% in its price and distributed US$ 0,00 in dividends, resulting in a Dividend Yield of 0,00%. The total shareholder return was 24,18%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How to buy stocks of United Therapeutics (UTHR)?

Investing in stocks of United Therapeutics (UTHR) can be done in two ways: by buying the stock no exterior. A stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much do 100 stocks of United Therapeutics (UTHR) yield today?

The yield of United Therapeutics (UTHR) was 10,97% in the last month, 24,18% in the last year and 322,06% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of US$ 0,00 in dividends, um Dividend Yield de 0,00%.

If you wanted to buy 100 stocks of United Therapeutics (UTHR) today, the total investment would be US$ 44.000,00, based on the current price of US$ 440,00.

If past performance were to repeat, the return on your investment would be:

In 1 year: US$ 54.639,20
In 5 years: US$ 185.706,40
In 10 years: 157.040,40

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

UTHR

United Therapeutics Corporation

Price

variation (12m)

p/l

p/vp

DIVIDEND YIELD

Profitability of UTHR

check out the fundamentals of United Therapeutics shares

P/E

P/SALES RATIO (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

P/EBITDA

P/EBIT

P/ASSET

BVPS

EPS

EQUITY / ASSETS

CAGR REVENUES 5 YEARS

CAGR PROFITS 5 YEARS

Graham's Fair Price

If you had invested (change) 2 years years ago, ago, today you would have

current DY: 0,00%

5-year average DY: 0,00%

ABOUT THE COMPANY United Therapeutics

United Therapeutics Corporation

Estados Unidos

29 years

1999

920

PROFIT X PRICE UTHR

UTHR results

UTHR cash flow

evolution of assets - UTHR

UTHR balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

Frequently Asked Questions